Impact of pretransplant rituximab induction on highly sensitized kidney recipients: Comparison with non-rituximab group

Journal of the Korean Surgical Society

Volumn 82, Issue 6, 2012, Pages 335-339

  Song, Young Hae ^a   Huh, Kyu Ha ^a   Kim, Yu Seun ^a   Lee, Hyung Soon ^a   Kim, Myoung Soo ^a   Kim, Soo Jin ^b   Kim, Hyun Jung ^a   Kim, Soon Il ^a   Joo, Dong Jin ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Immunological sensitization; Kidney transplantation; Rituximab

Indexed keywords

EID: 84863663415     PISSN: 12260053     EISSN: 20930488     Source Type: Journal    
DOI: 10.4174/jkss.2012.82.6.335     Document Type: Conference Paper

References (21)

1. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003;3:653-64. (Pubitemid 36745237)
2. Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006;1:421-32.
3. Iwaki Y, Terasaki PI. Sensitization effect. Clin Transpl 1986:257-65.
4. Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Collins AB, Fitzpatrick D, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001;71:652-8. (Pubitemid 32268068)
5. Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 2005;19:137-40. (Pubitemid 40227865)
6. Aranda JM Jr, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002;73:907-10. (Pubitemid 34252353)
7. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996-1001. (Pubitemid 38745599)
8. Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006;2:221-30. (Pubitemid 43787288)
9. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349:125-38. (Pubitemid 36818782)
10. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-14. (Pubitemid 36745243)
11. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG de-sensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346-51. (Pubitemid 43382170)
12. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Dan-guilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc 2008;40:2218-21.
13. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004;77:542-8. (Pubitemid 38282809)
14. Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74. (Pubitemid 27419340)
15. Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83:1277-80. (Pubitemid 46743692)
16. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006;6:2418-28. (Pubitemid 44359429)
17. Yoon HE, Hyoung BJ, Hwang HS, Lee SY, Jeon YJ, Song JC, et al. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J Korean Med Sci 2009;24 Suppl:S148-55.
18. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-doserituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009;22:447-54.
19. Tyden G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009;87:1325-9.
20. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rit-uximab in patients with chronic lymphocytic leukemia. Blood 2003;102:3514-20. (Pubitemid 37419939)
21. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood 2004;103:3989-90.